Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Oxidronate→

Oxidronate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
15468-10-7
Molecular formula
CH6O7P2
Molecular weight
192 g/mol
Drug class
Bisphosphonate liganddiagnostic radiopharmaceutical precursor for technetium-99m bone imaging
Mechanism of action
Oxidronate (hydroxymethylene diphosphonate, HMDP/HDP) chelates technetium-99m in radiopharmaceutical kits. The labelled complex localises to hydroxyapatite at sites of increased osteoblastic activity, permitting skeletal scintigraphy.
Indications / reported uses
  • Used as the active ligand in technetium-99m oxidronate (HDP/HMDP) for skeletal scintigraphy and assessment of areas of increased bone turnover. Diagnostic imaging uses the technetium-labelled formulation.

Sources: https://www.ncbi.nlm.nih.gov/mesh?term=%22technetium+Tc+99m+hydroxymethylene+diphosphonate%22 · https://www.ncbi.nlm.nih.gov/sites/books/NBK531486/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Oxidronate Environmental Risk Assessment (ERA) (the Oxidronate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.